**Core tip:** To identify the influence on the gut microbial community between ulcerative colitis (UC) patients and their healthy partners, we investigated the gut bacterial community using 16S rRNA amplicon sequencing. The results showed that fecal microbial communities were more similar in UC patients, which had a lower relative abundance of Firmicutes bacteria. Microbiota dysbiosis was also founded in healthy partners. The pathways involved in lipid and nucleotide metabolism were more abundant in the UC patients. The membrane transport and metabolism of cofactors and vitamins pathways were significantly enriched in the healthy partners. Microbial composition might be affected in healthy partners cohabiting with UC patients.

INTRODUCTION
============

Ulcerative colitis (UC), one of the main types of inflammatory bowel disease (IBD), has become increasingly prevalent in developed countries over the past two decades\[[@B1]\]. However, according to the latest Asian epidemiological investigation, the incidence of the IBD has expanded dramatically into developing countries with the increased westernization of lifestyles\[[@B1],[@B2]\].

UC is a multi-faceted disorder associated with a germline genetic background, an aberrant immune system response, and environmental factors\[[@B3]\]. Recently, the gut microbial community has attracted substantial research attention, especially in terms of its influence in healthy and IBD patients\[[@B4]-[@B6]\]. Some alterations in the microbial community are shared in Crohn's disease (CD) and UC patients relative to healthy people, including reduced gut microbiota diversity (particularly *Firmicutes*), the presence of non-commensals, and increased abundance of pathogenic Proteobacteria strains\[[@B7],[@B8]\]. However, some alterations in the bacterial community are specific to UC. For example, an increased presence of *Escherichia coli* and *Fusobacterium spp* group\[[@B6]\], as well as a reduction in *Clostridium coccoides* group, has been reported in UC patients\[[@B9]\].

Previous studies have demonstrated that environmental factors, including dietary age\[[@B9]\], habits\[[@B10]\], and obesity\[[@B11]\], impact the composition of the gut microbiota. Consequently, we wondered whether the cohabitation environment can influence the microbial community. In 1994, an investigation of 10 couples showed that individuals with IBD symptoms before marriage influenced their partners, resulting in similar symptoms in couples\[[@B12]\]. However, these results mainly focused on clinical symptoms and did not involve the gut microbial community.

Profiling the fecal microbiome using methods based on analysis of the 16S ribosomal RNA gene is less biased than cultivation-based approaches. In recent years, bacterial 16S rRNA amplicon sequencing, referred to as "16S rRNA gene sequencing", has been used widely for the metagenomic analysis of the environment, including analysis of the composition of human and animal gut and fecal microbiota\[[@B13],[@B14]\]. In particular, compared with bacterial culture, 16S rRNA gene sequencing has a huge advantage in identifying new pathogens or difficult to culture bacteria compared with culture-independent methods. Compared with other high-throughput sequencing platforms (pyrosequencing, Life Technologies platform), the MiSeq platform generates the highest base sequence accuracy with little limitation on the DNA input\[[@B15],[@B16]\]. Although the cohabitation environment has been studied using 16S rRNA gene sequencing, many studies on the gut microbial community of IBD patients focused on comparisons between twins and siblings\[[@B11],[@B17]\].

This study aimed to explore deeply the composition of the UC gut bacterial community using 16S rRNA sequencing to identify the influence on the gut microbial community between couples. Additionally, the current study investigates the predominant fecal microbiota of UC patients compared with their healthy cohabiting partners.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

The diagnosis of UC was determined by endoscopic and pathological findings, and patients diagnosed with UC for longer than 3 mo were recruited from Lishui People's Hospital at Zhejiang Province. Healthy couples composing the control group, were recruited from a common living environment cohabiting with the UC patients. All participants in this study were divided into two groups (*n* = 8 each) according to their disease status. Group A consisted of UC patients, identified as UC1-UC8. Group B consisted of their healthy partners, termed HF1-HF8. The study was approved by the Ethics Committee of the hospital and all participants provided written informed consent upon enrolment.

Sample collection and DNA extraction
------------------------------------

Fecal samples were collected from all participants and were immediately stored at -80 °C until further processing. The total DNA was extracted from 200 mg of fecal sample using the QIAamp DNA Stool Mini Kit (Qiagen, Inc., Valencia, CA, United States), according to the manufacturer's instructions. The DNA concentration was quantified using a Qubit 2.0 Fluorometer and diluted appropriately based on the total DNA concentration.

16S amplicon-sequencing
-----------------------

The variable regions V3 and V4 of the bacterial 16S rRNA gene were amplified using a two-step PCR protocol. In brief, the first PCR was performed with universal primers (356F 5'-CCTACGGGNGGCWGCAG-3' and 803R 5'-GACTACHVGGGTATCTAATCC-3') and an attached overhang adapter (forward primer overhang adapter 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' and reverse primer overhang adapter 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3'). The first PCR reaction mixture (20 μL) contained 10 ng of DNA template, 10 μL of 2 × High-Fidelity PCR Master Mix with HF Buffer (New England Biolabs, Ipswich, MA, United States), each primer at 5 μmol/L, and reagent-grade water (Sigma Aldrich, St. Louis, MO, United States). The first PCR program for V3 and V4 comprised an initial denaturation of 95 °C for 3 min; followed by 25 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, extension at 72 °C for 30 s; and a final extension at 72 °C for 5 min. Then, the PCR product was cleaned using AMPure XP DNA purification beads (Beckman Coulter, Danvers, MA, United States), according to the manufacturer's instructions. The second PCR reaction mixture (25 μL) contained 2 μL of cleaned PCR products; 12.5 μL of 2 × High-Fidelity PCR Master Mix and HF Buffer; P5/P7 primers, including adapters and sample barcodes (Illumina); and reagent-grade water. The second PCR program was similar to the first PCR program except the annealing temperature was at 50 °C and the program comprised 10 cycles. Finally, the PCR product was purified using AMPure XP beads to remove primer dimers and was then quantified on an Agilent Bioanalyzer 2100 using High Sensitivity DNA chips (Agilent Technologies, Santa Clara, CA, United States). The library of each sample was pooled at an equimolar concentration, and sequencing was performed on the Illumina MiSeq platform to generate 2 × 250 bp paired-end reads.

Taxonomic classification and pathway profiles of 16S rRNA gene sequencing data
------------------------------------------------------------------------------

We merged the paired-end reads using FLASH v1.2.11 and obtained approximately 460 bp V3-V4 16S sequences. Merged reads were processed with QIIME v1.8.0, which removed reads with N bases and trimmed reads with more than three consecutive low-quality bases (Q \< 20). The reads the passed the high quality filters were aligned to the Greengenes Database (Aug, 2013 version), and USEARCH v6.1 was applied for chimera checking. Then, UCLUST v1.2.22 was used for operational taxonomic unit (OTU) clustering at the 97% sequence similarity level. Each OTU was classified according to an assignment of the taxonomic rank using the reference dataset from the Ribosomal Database Project (version 2.2). Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis was performed to generate Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway profiles as previously described\[[@B18],[@B19]\].

Statistical analysis
--------------------

Correlations between the overlapping genera of the 16S rRNA gene sequencing were identified using Pearson's correlation in the R language. The Wilcoxon rank-sum test (R v3.1.2) was employed to detect interindividual differences. Under the condition of multiple comparisons, *P* values were corrected to control for the false-discovery rate. Differences with *P* value \< 0.05 were considered statistically significant.

RESULTS
=======

Study subjects and 16S rRNA sequencing
--------------------------------------

To measure the compositional and functional differences in the common living environment between the gut microbiota of the UC patients and healthy individuals, 16 fecal samples were collected from eight families, including eight UC patients and eight healthy control partners. All patients in this study were cohabiting with their partners. The demographics and characteristics of 8 UC patients and their partners are shown in Table [1](#T1){ref-type="table"}.

###### 

Information and clinical characteristics of ulcerative colitis patients and their healthy partners *n* (%)

                                 **UC patients (*n* = 8)**   **Healthy partners (*n* = 8)**
  ------------------------------ --------------------------- --------------------------------
  mean age (SD)                  53 (9.57)                   42.25 (9.41)
  Male                           6 (75.0)                    3 (37.5)
  Age at diagnosis                                           
  16-40 yr                       3 (37.5)                    
  Above 40 yr                    5 (62.5)                    
  Disease location                                           
  Colonic                        5 (62.5)                    
  Rectal                         3 (37.5)                    
  Concomitant upper GI disease   4 (50.0)                    
  CRP                                                        
  Normal (0-10 mg/L)             5 (62.5)                    
  Abnormal                       3 (37.5)                    

GI: Gastrointestinal; CRP: C-reactive protein; UC: Ulcerative colitis.

16S rRNA amplicon-sequencing of fecal DNA samples was performed using next-generation sequencing (NGS) technology. Low quality reads and chimera sequences were filtered from the raw data, eventually producing an average of 47469 reads per sample. These reads corresponded to 1137 operational taxonomic units (OTUs) at the 97% sequence similarity level and identified 167 genera. There was no significant difference between the number of OTUs in UC patients and their partners (947 ± 298.4 for UC patients and 1327.1 ± 419.9 for their partners, *P* = 0.071).

Microbiota diversity and similarity analyses
--------------------------------------------

We used three metrics to characterize the fecal microbiota diversity between UC patients and their partners. Microbial alpha diversity was not significantly different by Chao1 analysis (*P* = 0.573). Additionally, there were no significant differences observed by Shannon-Wiener (*P* = 0.505) or Simpson's indices (*P* = 0.574). The distribution of fecal microbiota was determined using Bray Curtis similarities analysis. The entire microbiota of UC patients was not significantly divergent from those of their cohabiting partners (*P* = 0.449). However, using un-weighted analysis, the microbiota composition was more similar among UC patients than it was to that of their partners (Figure [1](#F1){ref-type="fig"}, *P* = 0.024). These results indicated that cohabitation with UC patients might influence the fecal microbiota composition of healthy people; however, higher dissimilarity of the microbiota was observed among the healthy partners.

![Distributions of the unweighted unifrac distance within the ulcerative colitis patients and healthy partners groups. Orange and red boxplots denote the distributions of 16S rRNA gene sequencing of fecal samples in ulcerative colitis patients and healthy partners, respectively.](WJG-23-4624-g001){#F1}

Microbial composition
---------------------

Although there was no significant difference in overall microbial diversity, the Wilcoxon test indicated that some bacteria were significantly different between UC patients and their partners. As shown in Figure [2](#F2){ref-type="fig"}, at the genus level, 10 genera were less abundant in the fecal microbiota of UC patients compared with that in their healthy partners, and only one bacterium was more abundant in the UC patients (*P* \< 0.05). At the phylum level, nine significantly different bacteria species belonged to the *Firmicutes*, and the other bacteria were classified as *Actinobacteria* and *Bacteroidetes*.

![Significant differences in the fecal microbiota composition between ulcerative colitis patients and their healthy partners. Comparisons for each sample were calculated using the Wilcoxon test. The down arrows indicate less abundant microbiota in ulcerative colitis (UC) patients, and the up arrow represents the more abundant microbiota in UC patients compared with their healthy partners.](WJG-23-4624-g002){#F2}

In this study, the fecal microbiota in the UC patients showed a decrease in the *Firmicutes* bacteria, especially *Blautia*, *Clostridium, Coprococcus*, and *Roseburia*. *Blautia* was detected at 5.81% in the healthy partners, and this percentage was lower in the UC patients. *Clostridium* and *Coprococcus* accounted for 6.49% and 3.4% of the fecal microbiota of the healthy partners, whereas these genera were less abundant in the UC patients (0.96% and 0.45%, respectively). A similar trend was observed for *Roseburia*, which was present at 1.48% in the healthy partners and 0.15% in the UC patients. Other *Firmicutes* genera, such as *Anaerostipes Lachnospira*, *Megasphaera*, and *Turicibacter*, were resent at a very low abundance in the UC patients. Although they were not detected in all healthy partners, these rare species were detected at significantly different levels in the healthy partners compared with the UC patients. For example, *Anaerostipes* was detected in UC patients at a percentage of 0.006%, but at 0.68% in the healthy partners. Additionally, *Alistipes*, belonging to the *Bacteroidetes*, and an unclassified bacterium of *Actinobacteria*, did not appear in UC patients, but were detected in the healthy partners at low abundances of 0.14% and 0.23%, respectively.

Microbiota dysbiosis
--------------------

An unclassified bacterium belonging to the *Lactobacillales* was detected in a UC patient (UC1) with a higher relative abundance than in their partner (Figure [2](#F2){ref-type="fig"}, *P* = 0.032). The proportion of *Lactobacillus* genus showed large dysbiosis in patient UC1, accounting for 81.8% (Figure [3](#F3){ref-type="fig"}). Microbiota dysbiosis was also observed in other UC patients and their partners. In patient UC2, the first and second most abundant genera were *Bacteroides* and *Parabacteroides*, which were present in percentages of 58.63% and 28.93%, respectively (Figure [3](#F3){ref-type="fig"}). *Bacteroides* was also the dominant genus, accounting for 70.24% in patient UC6. In addition, the *Escherichia* genus accounted for 44.39% in patient UC5. For the healthy partners, microbiota dysbiosis was also found in a few individuals. For example, in HF6, the relative abundance of the *Klebsiella* genus reached 63.3%. *Akkermansia*, belonging to the *Verrucomicrobia* phylum, was only detected in patient UC4 and his partner, accounting for 18.46% and 68.74%, respectively (Figure [3](#F3){ref-type="fig"}). Microbiota dysbiosis destroys the gut microbiota composition and influences its normal function, which might accelerate the occurrence of intestinal disease.

![Relative abundance at the genus level, as shown by 16S rRNA gene sequencing, from ulcerative colitis patients and their partners showing a microbiota imbalance. Each column represents one fecal sample and different colors indicate different genera in the microbiota composition. Microbiota with a substantial proportional imbalance are listed. UC: UC patient; HF: Healthy partners.](WJG-23-4624-g003){#F3}

Microbial metabolic pathways
----------------------------

Combining the microbial composition with a genome database from KEGG (Kyoto Encyclopedia of Genes and Genomes), 328 pathways were identified. We continued our analysis using the Wilcoxon test, and 20 of 328 (6.09%) total metabolic pathways were differentially abundant at *Q* \< 0.05 between the UC patients and their healthy partners. In the UC patients, we observed that 10 pathways were increased significantly, especially those concerning lipid metabolism and nucleotide metabolism. Another eight pathways, such as those involving membrane transport and metabolism of cofactors and vitamins, were more abundant in the healthy partners (Table [2](#T2){ref-type="table"}).

###### 

Microbial metabolism differentially abundant in ulcerative colitis patients and their healthy partners

  **Pathway**                                                             **UC patients**   **Healthy partners**   ***P* value**                   
  ----------------------------------------------------------------------- ----------------- ---------------------- --------------- --------------- ----------
  Membrane transport                                                                                                                               
  ABC transporters[1](#T2FN1){ref-type="table-fn"}                        3.0271            0.5695                 3.7117          0.7130          0.04149
  Signal transduction                                                                                                                              
  Phosphatidylinositol signaling system                                   0.1022            0.0155                 0.0845          0.0182          0.018959
  Signaling molecules and interaction                                                                                                              
  G protein-coupled receptors[1](#T2FN1){ref-type="table-fn"}             1.76 × 10^-5^     3.63 × 10^-5^          6.54 × 10^-5^   1.02 × 10^-5^   0.02515
  Infectious diseases                                                                                                                              
  Staphylococcus aureus infection                                         0.295             0.582                  0.00545         0.00442         0.041492
  Biosynthesis of other secondary                                                                                                                  
  Metabolites; isoflavonoid biosynthesis                                  8.97 × 10^-6^     8.03 × 10^-6^          9.75 × 10^-7^   1.39 × 10^-7^   0.003511
  Novobiocin biosynthesis[1](#T2FN1){ref-type="table-fn"}                 0.1161            0.010                  0.1277          0.0122          0.02494
  Carbohydrate metabolism                                                                                                                          
  C5-Branched dibasic acid metabolism[1](#T2FN1){ref-type="table-fn"}     0.287             0.0536                 0.3214          0.0218          0.04149
  Glycan biosynthesis and metabolism                                                                                                               
  Glycosphingolipid biosynthesis                                          3.74 × 10^-4^     3.95 × 10^-4^          1.37 × 10^-4^   1.91× 10^-4^    0.032476
  Lipid metabolism                                                                                                                                 
  Linoleic acid metabolism                                                0.0851            0.0505                 0.0518          0.0197          0.024942
  Primary bile acid biosynthesis                                          0.0416            0.0186                 0.0257          0.0120          0.018959
  Secondary bile acid biosynthesis                                        0.0414            0.0187                 0.0255          0.0120          0.018959
  Metabolism of cofactors and vitamins                                                                                                             
  Porphyrin and chlorophy II metabolism[1](#T2FN1){ref-type="table-fn"}   0.7225            0.1723                 0.8785          0.1079          0.03248
  Nucleotide metabolism                                                                                                                            
  Purine metabolism                                                       2.2171            0.2176                 2.0283          0.1561          0.018959
  Xenobiotics biodegradation and metabolism                                                                                                        
  Atrazine degradation[1](#T2FN1){ref-type="table-fn"}                    0.0227            0.0252                 0.0441          0.0329          0.03248
  Ethylbenzene degradation                                                0.0769            0.0643                 0.0429          0.00795         0.018959
  Naphthalene degradation                                                 0.1827            0.0823                 0.1300          0.0261          0.018959
  Nitrotoluene degradation[1](#T2FN1){ref-type="table-fn"}                0.0651            0.0346                 0.1022          0.0198          0.02494
  Styrene degradation[1](#T2FN1){ref-type="table-fn"}                     0.0155            0.0131                 0.0329          0.0231          0.02494

Indicated higher abundance in the healthy partners (*P* \< 0.05). UC: Ulcerative colitis.

The lipid metabolic pathway, including primary bile acid biosynthesis, secondary bile acid biosynthesis (*P* = 0.019), and linoleic acid (*P* = 0.025), was enriched significantly in the UC patients. The pathway involved in purine metabolism was also enriched in the UC patients (*P* = 0.019). In contrast, there was a decrease in porphyrin and chlorophyll metabolism in the UC patients (*P* = 0.032). In addition, the microbiota of the UC patients had fewer ABC transporters for membrane transport (*P* = 0.041).

DISCUSSION
==========

Alteration in the composition of the gut microbiota and decreases in community diversity are associated with the pathogenesis of UC\[[@B20]\]. However, our understanding of the interaction between couples cohabiting a shared environment in terms of their microbiota is poor. In this study, we analyzed the differences in the bacterial profiles and metabolic pathways between UC patients and their cohabiting partners. Marked microbiota dysbiosis and reduction of the diversity of *Firmicutes* were observed. Furthermore, to understand the functions of the different bacteria, we compared the differences in microbial metabolic pathways. Lipid metabolism and the biosynthesis of bile acids were significantly upregulated in the microbiota of the UC patients.

Unlike previous reports, we did not observe a significant difference in the OTU distribution associated with the disease state\[[@B21]\]. Additionally, we did not identify significant differences between UC patients and their partners in terms of the microbial alpha diversity using the Chao1, Shannon, and Simpson's indices\[[@B20],[@B22]\]. In contrast, we confirmed a compositional similarity between UC patients and their partners. Although there was no direct evidence that gut microbiota could spread between IBD patients and normal individuals, the results of this study suggested that fecal microbiota likely influence each other during long-term cohabitation with UC patients. Remarkably, our results indicated that the fecal microbiota composition was more similar among UC patients than among healthy individuals (Figure [1](#F1){ref-type="fig"}). These findings further demonstrated that the gut microbiota composition, and alterations to it, plays a crucial role in the occurrence of UC.

Although the cause of UC has many uncertain factors, gut microbiota dysbiosis has been considered a major trigger of inflammation\[[@B23]\]. Consistent with previous studies\[[@B22],[@B24]\], we also found that the fecal microbiota in the UC patients in the present study had a decrease in *Firmicutes* bacteria, especially in *Blautia*, *Clostridium*, *Coprococcus*, and *Roseburia* bacteria (Figure [2](#F2){ref-type="fig"}). Although we realized that the gut microbial composition and its interaction with the host likely play an important role in IBD, the relationship between these has remained a mystery. Our research further confirmed that *Firmicutes* plays a crucial role in UC patients. The reduction in *Clostridium* likely decreased the utilization of short chain fatty acids and butyric acid salt in intestinal epithelial cells and induced inflammation. The depletion of *Actinobacteria* and *Bacteroidetes* is controversial, and we found that these bacteria were greatly depleted\[[@B21],[@B25],[@B26]\].

Interestingly, comparison of the relative abundance at the genus level using 16S rRNA gene sequencing from UC patients and their partners demonstrated that the composition of the fecal microbiota was dominated by *Bacteroides* in patients UC2 and UC6. By contrast, other samples, including those from healthy partners, did not show this situation. Additionally, among the healthy partners, HF4 and HF6 were dominated by *Akkermansia* and *Klebsiella*, respectively. We speculated that this microbiota dysbiosis is likely a consequence of interaction in the same environment.

In agreement with previous studies, we observed that lipid metabolism was remarkably increased\[[@B27]\]. Previous studies have suggested that commensal bacteria might increase or decrease certain specific metabolic pathways to participate in competition for limited energy resources while living in the host intestinal environment. Davenport et al\[[@B27]\] posited that because of a lack of carbohydrates in the inflamed regions, such as in the case of mucin production dysfunction, gut commensal bacteria start metabolizing lipids and amino acids for necessary nutrients. This hypothesis was supported by the decrease in *Firmicutes*, which are unable to utilize amino acids for energy\[[@B27],[@B28]\].

Furthermore, one study found that patients with IBD may also suffer from the co-occurrence of primary biliary cirrhosis\[[@B29]\]. In the present study, we observed a significant increase in both primary bile acid biosynthesis and secondary bile acid biosynthesis of lipids (*P* = 0.019) in the UC patients (Table [2](#T2){ref-type="table"}). In healthy individuals, it is difficult to detect bile acid in the blood. However, when liver cells are damaged, bile acid biosynthesis is abnormal and its concentration increases. We speculated that the increase in bile acid biosynthesis in UC patients might be associated with frequent liver disease, such as chronic liver disease or alloimmune liver disease. Of course, liver cell damage was also related to drug toxicity produced by long term medication and immune deficiency in UC patients. This would lead to oxidative stress, and some bacteria need to maintain homeostasis under oxidative stress. Interestingly, we observed an increase in linoleic acid metabolism in the UC patients (*P* = 0.025). Linoleic acid is a type of unsaturated fatty acid that is associated with prostaglandin biosynthesis, which could participate in liver injury protection.

In conclusion, this study presents a comprehensive evaluation of the bacterial composition and the differences in the pathways of UC fecal microbiota. Although our results were similar to the results of previous studies, we also identified an increased prevalence of lipid metabolic pathways and bile acid biosynthesis. The gut microbiota of the UC patients and their partners likely influenced each other. Furthermore, we verified that microbiota dysbiosis is more likely a consequence, rather than a cause, of inflammation.

COMMENTS
========

Background
----------

Ulcerative colitis (UC) is one of the main types of inflammatory bowel disease. Compared with healthy people, some alterations in the microbial community are shared in Crohn's disease and UC patients. However, some alterations in the bacterial community are specific to UC patients. The authors wondered whether cohabitation could influence the microbial community. Previous studies mainly focused on clinical symptoms and did not involve gut microbial community. Profiling the fecal microbiome using methods based on analysis of the 16S ribosomal RNA gene is less biased than cultivation-based approaches. Therefore, we investigated the gut bacterial community between UC patients and their healthy partners using 16S rRNA amplicon sequencing.

Research frontiers
------------------

Recently, the gut microbial community has attracted substantial attention, especially the influence in healthy and inflammatory bowel disease (IBD) patients. Some studies have demonstrated that environmental factors, including dietary age, habits, and obesity, impact the composition of the gut microbiota.

Innovations and breakthroughs
-----------------------------

This study is the first to investigate the influence on the gut microbial community between UC patients and their cohabiting healthy partners. This study showed that microbial composition might affect healthy partners cohabiting with UC patients, especially in terms of microbiota dysbiosis.

Applications
------------

In this study, the authors analyzed the differences in the bacterial profiles and metabolic pathways between UC patients and their cohabiting partners. The findings further demonstrated that the gut microbiota composition and alterations play a crucial role in the occurrence of UC. Furthermore, the gut microbiota of the UC patients and their partners likely influence each other.

Terminology
-----------

16S rRNA gene sequencing is a non-culture method based on high-throughput sequencing. At present, 16S rRNA gene sequencing has been utilized widely for metagenomic analysis of the environment, including analysis of the composition of the human and animal guts and fecal microbiota.

Peer-review
-----------

Gut dysbiosis is considered one of the factors inducing inflammation in chronic IBD; however, its role in the etiology of ulcerative colitis is controversial. There have been many studies on fecal microbiota in recent years. The present study used a very sensitive method to assess bacterial strains and compared the microbiota in patients with inflammatory bowel disease with that of their healthy partners. The study assessed some type of bacteria only found in patients with UC. These bacteria are difficult to detect using less sensitive methods.
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